Cardiac Remodeling Biomarkers as Potential Circulating Markers of Left Ventricular Hypertrophy in Heart Failure with Preserved Ejection Fraction

Soluble suppressor of tumorigenicity 2 (sST2), galectin-3, growth differentiation factor (GDF)-15 and syndecan-1 represent biomarkers of cardiac remodeling, involved in heart failure (HF) progression. We hypothesize that their plasma concentrations, together with brain natriuretic peptide (BNP), are...

Full description

Saved in:

Bibliographic Details
Published in:	The Tohoku Journal of Experimental Medicine Vol. 250; no. 4; pp. 233 - 242
Main Authors:	Mitic, Valentina T., Stojanovic, Dijana R., Ilic, Marina Z. Deljanin, Stojanovic, Miodrag M., Petrovic, Dejan B., Ignjatovic, Aleksandra M., Stefanovic, Nikola Z., Kocic, Gordana M., Bojanic, Vladmila V.
Format:	Journal Article
Language:	English
Published:	Japan Tohoku University Medical Press 01-04-2020
Subjects:	Biomarkers - blood Case-Control Studies Echocardiography Female galectin-3 growth differentiation factor-15 Heart Failure - blood Heart Failure - complications Heart Failure - diagnostic imaging Heart Failure - physiopathology Heart Ventricles - pathology Heart Ventricles - physiopathology Humans Hypertrophy, Left Ventricular - blood Hypertrophy, Left Ventricular - complications Hypertrophy, Left Ventricular - diagnostic imaging Hypertrophy, Left Ventricular - physiopathology Male mid-range ejection fraction Middle Aged Organ Size soluble suppressor of tumorigenicity 2 Stroke Volume - physiology syndecan-1 Ventricular Remodeling growth differentiation factor-15 mid-range ejection fraction syndecan-1 galectin-3 soluble suppressor of tumorigenicity 2
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Soluble suppressor of tumorigenicity 2 (sST2), galectin-3, growth differentiation factor (GDF)-15 and syndecan-1 represent biomarkers of cardiac remodeling, involved in heart failure (HF) progression. We hypothesize that their plasma concentrations, together with brain natriuretic peptide (BNP), are different in HF stratified by ejection fraction (EF), demonstrating correlations with echocardiographic parameters that indicate left ventricular (LV) hypertrophy; LV mass index (LVMI) and posterior wall and septum diameters. HF patients (n = 77) were classified according to EF: reduced EF < 40% (HFrEF), mid-range EF = 40-49% (HFmrEF), preserved EF > 50% (HFpEF). We found that plasma concentrations of four cardiac remodeling biomarkers were highest in HFrEF and lowest in HFpEF, p < 0.001. In HFpEF, remodeling biomarkers independently correlated with LVMI: sST2 (p = 0. 002), galectin-3 (p < 0.001), GDF-15 (p = 0.011), and syndecan-1 (p = 0.006), whereas galectin-3 correlated after multivariable adjustments (p = 0.001). Independent correlates of septum and posterior wall diameters, in HFpEF, were sST2 (p = 0.019; p = 0.026), galectin-3 (p = 0.011; p = 0.009), GDF-15 (p = 0.007; p = 0.001), and syndecan-1 (p = 0.005; p = 0.002). In HFrEF, only sST2, adjusted, correlated with LVMI (p = 0.010), whereas BNP correlated with LVMI (p = 0.002) and EF (p = 0.001). GDF-15 correlated with diastolic dysfunction in HFpEF (p = 0.046) and HFrEF (p = 0.024). Cardiac remodeling biomarkers are potential circulating indicators of LV hypertrophy in HFpEF, which may ensure timely recognition of disease progression among high-risk patients.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0040-8727 1349-3329
DOI:	10.1620/tjem.250.233